Price (delayed)
$0.2227
Market cap
$14.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.58
Enterprise value
$17.43M
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose
There are no recent dividends present for LYRA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.